Integer Holdings Corporation Reports Third Quarter 2024 Results

GlobeNewswire10-24

~ Continued strong performance with 3Q24 financial results ~~ Raising midpoint of 2024 operating profit and EPS outlook ~ PLANO, Texas, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477682169?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/p2t2G1tgcV_UVWHOcZEQ1A--~B/aD05NDM7dz0yMTUzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/330a5b736e07b05c5c5e1b81145c68b5","is_english":true,"pubTime":"2024-10-24 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2477682169","market":"us","top_or_hot":-1,"title":"Integer Holdings Corporation Reports Third Quarter 2024 Results","media":"GlobeNewswire","content":"<div>\n<p>~ Continued strong performance with 3Q24 financial results ~~ Raising midpoint of 2024 operating profit and EPS outlook ~\nPLANO, Texas, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (...</p>\n\n<a href=\"https://finance.yahoo.com/news/integer-holdings-corporation-reports-third-120000699.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Integer Holdings Corporation Reports Third Quarter 2024 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInteger Holdings Corporation Reports Third Quarter 2024 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-24 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/integer-holdings-corporation-reports-third-120000699.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>~ Continued strong performance with 3Q24 financial results ~~ Raising midpoint of 2024 operating profit and EPS outlook ~\nPLANO, Texas, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (...</p>\n\n<a href=\"https://finance.yahoo.com/news/integer-holdings-corporation-reports-third-120000699.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/integer-holdings-corporation-reports-third-120000699.html","article_id":"2477682169","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/p2t2G1tgcV_UVWHOcZEQ1A--~B/aD05NDM7dz0yMTUzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/330a5b736e07b05c5c5e1b81145c68b5"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477682169","pubTimestamp":1729771200,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"~ Continued strong performance with 3Q24 financial results ~~ Raising midpoint of 2024 operating profit and EPS outlook ~PLANO, Texas, Oct. 24, 2024  -- Integer Holdings Corporation  today announced results for the three and nine months ended September27, 2024.Our previously announced sale of the Electrochem business for $50 million in cash remains on track and is expected to close later this month. Except for cash flow measures, prior period amounts have been recast to exclude the Electrochem business, which is a discontinued operation, consistent with GAAP continuing operations presentation. Unless otherwise stated, all results and comparisons set forth in this release are presented on a continuing operations basis.“Third quarter year to date, Integer delivered 10% sales growth and a 23% increase in adjusted operating income versus a year ago,” said Joseph Dziedzic, Integer’s president and CEO. “We expect 2024 sales growth of 10% to 11% with above-market organic sales growth of 7% to","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","ITGR":"Integer Holdings Corporation","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0566484027.USD":"安本美国小盘成长股","CDMO":"Avid Bioservices, Inc.","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4082":"医疗保健设备"},"translate_title":"Integer Holdings Corporation报告2024年第三季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMO":1,"ITGR":1},"content_text":"~ Continued strong performance with 3Q24 financial results ~~ Raising midpoint of 2024 operating profit and EPS outlook ~\nPLANO, Texas, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three and nine months ended September 27, 2024.\nOur previously announced sale of the Electrochem business for $50 million in cash remains on track and is expected to close later this month. Except for cash flow measures, prior period amounts have been recast to exclude the Electrochem business, which is a discontinued operation, consistent with GAAP continuing operations presentation. Unless otherwise stated, all results and comparisons set forth in this release are presented on a continuing operations basis.\nThird Quarter 2024 Highlights (compared to Third Quarter 2023, except as noted)\n\nSales increased 9% to $431 million, with organic growth of 4%.\nGAAP income from continuing operations increased $8 million to $36 million, an increase of 29%. Non-GAAP adjusted net income increased $6 million to $50 million, an increase of 14%.\nGAAP operating income increased $9 million to $58 million, an increase of 19%. Non-GAAP adjusted operating income increased $11 million to $76 million, an increase of 17%.\nGAAP diluted EPS from continuing operations increased $0.18 per share to $1.01 per share. Non-GAAP adjusted EPS increased $0.14 per share to $1.43 per share.\nAdjusted EBITDA increased $15 million to $96 million, an increase of 18%.\nFrom the end of 2023, total debt increased $119 million to $1.079 billion and net total debt increased $105 million to $1.055 billion, primarily to finance the acquisition of Pulse Technologies, resulting in a leverage ratio of 3.0 times adjusted EBITDA as of September 27, 2024.\n\nThird Quarter 2024 YTD Highlights (compared to Third Quarter 2023 YTD, except as noted)\n\nSales increased 10% to $1.267 billion, with organic growth of 6%.\nGAAP income from continuing operations increased $26 million to $88 million, an increase of 41%. Non-GAAP adjusted net income increased $25 million to $133 million, an increase of 23%.\nGAAP operating income increased $31 million to $151 million, an increase of 26%. Non-GAAP adjusted operating income increased $40 million to $209 million, an increase of 23%.\nGAAP diluted EPS from continuing operations increased $0.64 per share to $2.49 per share. Non-GAAP adjusted EPS increased $0.67 per share to $3.87 per share.\nAdjusted EBITDA increased $48 million to $266 million, an increase of 22%.\n\n“Third quarter year to date, Integer delivered 10% sales growth and a 23% increase in adjusted operating income versus a year ago,” said Joseph Dziedzic, Integer’s president and CEO. “We expect 2024 sales growth of 10% to 11% with above-market organic sales growth of 7% to 8%. We are raising the midpoint of our full year adjusted operating income outlook by $4 million dollars, to 20% year over year, up from 18% in our previous outlook.”\nMr. Dziedzic added, “The divestiture of Electrochem will make Integer a pure-play medical technology company and provides additional capital to invest in capabilities and capacity that support our targeted growth markets.”\nDiscussion of Product Line Third Quarter 2024 Sales\n\nCardio & Vascular sales increased 13% in the third quarter 2024 compared to the third quarter 2023, driven by new product ramps in electrophysiology and structural heart, and the InNeuroCo and Pulse acquisitions.\nCardiac Rhythm Management & Neuromodulation sales increased 3% in the third quarter 2024 compared to the third quarter 2023, driven by strong growth in emerging neuromodulation customers with PMA (pre-market approval) products.\nAdvanced Surgical, Orthopedics & Portable Medical sales increased 12% in the third quarter 2024 compared to the third quarter 2023, primarily driven by fulfillment timing of last-time-buy orders related to the planned multi-year Portable Medical exit announced in 2022.\n\n2024 Outlook(a)\n\nThe 2024 Outlook excludes Electrochem. As previously communicated, the prior 2024 outlook included the following estimated amounts for Electrochem: \n  \nSales of $36 million.\nGAAP operating income of $3 million. Non-GAAP adjusted operating income of $4 million.\nAdjusted EBITDA of $5 million.\nGAAP net income of $0 million. Non-GAAP adjusted net income of $1 million.\nGAAP diluted EPS of $0.00. Non-GAAP adjusted EPS of $0.02.\n$3 million of allocated interest expense as part of discontinued operations.\n \nUnless otherwise stated, 2024 Outlook and comparisons are presented on a continuing operations basis.\nWe have raised the midpoint of our full year profit and EPS outlook, compared to the 2024 outlook from July, revised to exclude Electrochem.\n\n\n\n\n(dollars in millions, except per share amounts)\nGAAP\n \nNon-GAAP(b)\n\n\n \nAs Reported\n \nChange from Prior Year\n \nAdjusted\n \nChange from Prior Year\n\n\nSales\n$1,707 to $1,727\n \n10% to 11%\n \nN/A\n \nN/A\n\n\nOperating income\n$205 to $213\n \n26% to 30%\n \n$280 to $288\n \n18% to 22%\n\n\nEBITDA\nN/A\n \nN/A\n \n$358 to $368\n \n18% to 21%\n\n\nIncome from continuing operations\n$122 to $128\n \n37% to 44%\n \n$181 to $188\n \n16% to 21%\n\n\nDiluted earnings per share\n$3.42 to $3.61\n \n30% to 37%\n \n$5.24 to $5.43\n \n14% to 18%\n\n\nCash flow from operating activities(c)\n$195 to $205\n \n8% to 14%\n \nN/A\n \nN/A\n\n\n\n\n\n\n(a)\nExcept as described below, further reconciliations by line item to the closest corresponding GAAP financial measure for adjusted operating income, adjusted EBITDA, adjusted net income and adjusted earnings per Share (“EPS”), included in our “2024 Outlook” above, and adjusted total interest expense, adjusted effective tax rate and leverage ratio in “Supplemental Financial Information” below, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from these non-GAAP financial measures.\n\n\n(b)\nAdjusted operating income for 2024 consists of GAAP operating income, excluding items such as amortization of intangible assets, restructuring and restructuring-related charges, and acquisition and integration costs, totaling approximately $75 million, pre-tax.Adjusted net income for 2024 consists of GAAP income from continuing operations, excluding items such as amortization of intangible assets, restructuring and restructuring-related charges, acquisition and integration costs, and gain or loss on equity investments totaling approximately $73 million, pre-tax. The after-tax impact of these items is estimated to be approximately $59 million, or approximately $1.67 per diluted share.Adjusted EPS for 2024 consists of GAAP diluted EPS from continuing operations, excluding the after-tax impact of the Adjusted net income items noted above and the estimated dilution resulting from the potential conversion of our 2028 Convertible Notes expected to be offset by capped call option contracts, which is approximately $0.15 per diluted share.Adjusted EBITDA is expected to consist of GAAP income from continuing operations, excluding items such as depreciation, interest, stock-based compensation and taxes totaling approximately $177 million to $181 million.\n\n\n(c)\nCash flows from operating activities includes an immaterial amount related to discontinued operations.\n\n\n\nPlease see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures.\nSupplemental Financial Information\n\n\n\n(dollars in millions)\n2024Outlook\n \n2023Actual\n\n\nDepreciation and amortization\n$106 to $110\n \n$96\n\n\nAdjusted total interest expense(a)\n$55 to $57\n \n$47\n\n\nStock-based compensation\n$24 to $25\n \n$23\n\n\nRestructuring, acquisition and other charges(b)\n$20 to $22\n \n$21\n\n\nAdjusted effective tax rate(c)\n18.0% to 19.0%\n \n17.6%\n\n\nLeverage ratio(d)\n2.6x to 2.7x\n \n3.1x\n\n\nCapital expenditures(e)\n$100 to $110\n \n$120\n\n\nCash income tax payments\n$36 to $40\n \n$30\n\n\n\n\n\n\n(a)\nAdjusted total interest expense refers to our expected full-year GAAP interest expense, expected to range from $55 million to $57 million for 2024, adjusted to remove the full-year impact of charges associated with the accelerated write-off of debt discounts and deferred issuance costs (loss on extinguishment of debt) included in GAAP interest expense, if any. Adjusted total interest expense of $46.8 million for 2023 consists of GAAP interest expense of $51.3 million less $4.5 million of losses from the extinguishment of debt.\n\n\n(b)\nRestructuring, acquisition and other charges consists of restructuring and restructuring-related charges, acquisition and integration costs, other general expenses and incremental costs of complying with the new European Union medical device regulations.\n\n\n(c)\nAdjusted effective tax rate refers to our full-year GAAP effective tax rate, expected to range from 18.0% to 19.0% for 2024, adjusted to reflect the full-year impact of the items that are excluded in providing adjusted net income and certain other identified items. Adjusted effective tax rate of 17.6% for 2023 consists of GAAP effective tax rate of 15.4% adjusted to reflect the impact on the income tax provision related to Non-GAAP adjustments.\n\n\n(d)\nPlease see “Notes Regarding Non-GAAP Financial Information” for additional information regarding leverage ratio.\n\n\n(e)\nCapital expenditures is calculated as cash used to acquire property, plant, and equipment (PP&E) less cash proceeds from the sale of PP&E.\n\n\n\nSummary Financial Results\n(dollars in thousands, except per share data)\n\n\n\n \nThree Months Ended\n \nNine Months Ended\n\n\n \nSeptember 27,2024\n \nSeptember 29,2023\n \nQTD Change\n \nSeptember 27,2024\n \nSeptember 29,2023\n \nYTD Change\n\n\nOperating income\n$\n58,011\n \n$\n    48,776\n \n18.9\n%\n \n$\n151,206\n \n$\n    119,791\n \n26.2\n%\n\n\nIncome from continuing operations\n$\n36,282\n \n$\n28,174\n \n28.8\n%\n \n$\n88,080\n \n$\n62,330\n \n41.3\n%\n\n\nDiluted EPS from continuing operations\n$\n1.01\n \n$\n0.83\n \n21.7\n%\n \n$\n2.49\n \n$\n1.85\n \n34.6\n%\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n\n\nEBITDA(a)\n$\n86,346\n \n$\n68,944\n \n25.2\n%\n \n$\n232,225\n \n$\n186,839\n \n24.3\n%\n\n\nAdjusted EBITDA(a)\n$\n95,526\n \n$\n80,681\n \n18.4\n%\n \n$\n265,597\n \n$\n217,669\n \n22.0\n%\n\n\nAdjusted operating income(a)\n$\n75,647\n \n$\n64,596\n \n17.1\n%\n \n$\n208,667\n \n$\n169,158\n \n23.4\n%\n\n\nAdjusted net income(a)\n$\n49,832\n \n$\n43,638\n \n14.2\n%\n \n$\n133,183\n \n$\n107,876\n \n23.5\n%\n\n\nAdjusted EPS(a)\n$\n1.43\n \n$\n1.29\n \n10.9\n%\n \n$\n3.87\n \n$\n3.20\n \n20.9\n%\n\n\n\n\n\n\n(a)\nEBITDA, adjusted EBITDA, adjusted operating income, adjusted net income, and adjusted EPS are non-GAAP financial measures. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures. Refer to Tables A, B and C at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.\n\n\n\nSummary Product Line Results(dollars in thousands)\n\n\n\n \nThree Months Ended\n\n\n \nSeptember 27,2024\n \nSeptember 29,2023\n \nQTD Change\n \nOrganic Change(a)\n\n\nProduct Line Sales\n \n \n \n \n \n \n \n\n\nCardio & Vascular\n$\n241,009\n \n$\n214,004\n \n 12.6\n%\n \n6.2\n%\n\n\nCardiac Rhythm Management & Neuromodulation\n \n165,094\n \n \n160,121\n \n3.1\n%\n \n2.2\n%\n\n\nAdvanced Surgical, Orthopedics & Portable Medical\n \n25,314\n \n \n22,678\n \n11.6\n%\n \n(1.0)%\n\n\nTotal Sales\n$\n431,417\n \n$\n396,803\n \n8.7\n%\n \n4.3\n%\n\n\n \n \n \n \n \n \n \n \n\n\n \nNine Months Ended\n\n\n \nSeptember 27,2024\n \nSeptember 29,2023\n \nYTD Change\n \nOrganic Change(a)\n\n\nProduct Line Sales\n \n \n \n \n \n \n \n\n\nCardio & Vascular\n$\n 694,278\n \n$\n   613,701\n \n13.1\n%\n \n6.5\n%\n\n\nCardiac Rhythm Management & Neuromodulation\n \n490,086\n \n \n459,643\n \n6.6\n%\n \n5.7\n%\n\n\nAdvanced Surgical, Orthopedics & Portable Medical\n \n82,735\n \n \n77,808\n \n6.3\n%\n \n6.5\n%\n\n\nTotal Sales\n$\n1,267,099\n \n$\n1,151,152\n \n10.1\n%\n \n6.2\n%\n\n\n\n\n\n\n(a)\nOrganic sales change is a non-GAAP financial measure. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts.\n\n\n\nConference Call Information\nThe Company will host a conference call on Thursday, October 24, 2024, at 8 a.m. CT / 9 a.m. ET to discuss these results. The scheduled conference call will be webcast live and is accessible through our website at investor.integer.net or by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (outside U.S.) and the conference ID is 4525826. The call will be archived on the Company’s website. An earnings call slide presentation containing supplemental information about the Company’s results will be posted to our website at investor.integer.net prior to the conference call and will be referenced during the conference call.\nFrom time to time, the Company posts information that may be of interest to investors on its website at investor.integer.net. To automatically receive Integer financial news by email, please visit investor.integer.net and subscribe to email alerts.\nAbout Integer®\nInteger Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.\nInvestor Relations:\nAndrew Senn763.951.8312andrew.senn@integer.net\nNotes Regarding Non-GAAP Financial Information \nIn addition to our results reported in accordance with generally accepted accounting principles in the United States of America (“GAAP”), we provide adjusted net income, adjusted EPS, earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted operating income, and organic sales change. Unless otherwise indicated, all financial metrics presented reflect continuing operations only.\nAdjusted net income and adjusted EPS consist of GAAP income from continuing operations and diluted EPS from continuing operations, respectively, adjusted for the following to the extent occurring during the period: (i) amortization of intangible assets, (ii) restructuring and restructuring-related charges; (iii) acquisition and integration related costs; (iv) other general expenses; (v) (gain) loss on equity investments; (vi) extinguishment of debt charges; (vii) European Union medical device regulation incremental charges; (viii) inventory step-up amortization; (ix) unusual, or infrequently occurring items; (x) the income tax provision (benefit) related to these adjustments and (xi) certain tax items that are outside the normal tax provision for the period. Adjusted EPS is calculated by dividing adjusted net income by adjusted weighted average shares.\nThe weighted average shares used to calculate diluted EPS in accordance with GAAP includes dilution, when applicable, resulting from the potential conversion of our 2.125% Convertible Senior Notes due 2028 (the “2028 Convertible Notes”). In connection with the issuance of the 2028 Convertible Notes, we entered into capped call contracts which are expected to reduce the potential dilution on our common stock in connection with any conversion of the 2028 Convertible Notes, subject to a cap. Adjusted weighted average shares consists of GAAP weighted average shares used to calculate diluted EPS, excluding, when applicable, dilution resulting from the potential conversion of our 2028 Convertible Notes expected to be offset by the capped call contracts.\nEBITDA is calculated by adding back interest expense, provision for income taxes, depreciation expense, and amortization expense from intangible assets and financing leases, to income from continuing operations, which is the most directly comparable GAAP financial measure. Adjusted EBITDA consists of EBITDA plus adding back stock-based compensation and the same adjustments as listed above except for items (i), (vi), (x) and (xi). Adjusted operating income consists of operating income adjusted for the same items listed above except for items (v), (vi), (x) and (xi).\nOrganic sales change is reported sales growth adjusted to remove the impact of foreign currency, the contribution of acquisitions and the strategic exit of the Portable Medical market. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue. For contribution of acquisitions, we exclude the impact on the growth rate attributable to the contribution of acquisitions in all periods where there were no comparable sales. For the strategic exit of the Portable Medical market, we exclude the impact on the growth rate attributable to Portable Medical sales for all periods presented.\nWe believe that the presentation of adjusted net income, adjusted EPS, EBITDA, adjusted EBITDA, adjusted operating income, and organic sales change, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. In addition to the performance measures identified above, we believe that net total debt and leverage ratio provide meaningful measures of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments. Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. We calculate leverage ratio as net total debt divided by adjusted EBITDA for the trailing 4 quarters.\nForward-Looking Statements\nSome of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to: our 2024 outlook including future sales, expenses, and profitability; the timing for the closing of the Electrochem sale transaction; our ability to execute our business model and our business strategy; projected capital spending; and other events, conditions or developments that will or may occur in the future. You can identify forward-looking statements by terminology such as “outlook,” “projected,” “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “project,” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below.\nAlthough it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors and other risks and uncertainties that arise from time to time are described in Item 1A, “Risk Factors” of our Annual Report on Form 10-K and in our other periodic filings with the SEC and include the following:\n\noperational risks, such as our dependence upon a limited number of customers; pricing pressures and contractual pricing restraints we face from customers; our reliance on third-party suppliers for raw materials, key products and subcomponents; interruptions in our manufacturing operations; our ability to attract, train and retain a sufficient number of qualified associates to maintain and grow our business; the potential for harm to our reputation and competitive advantage caused by quality problems related to our products; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; global climate change and the emphasis on Environmental, Social and Governance matters by various stakeholders; our dependence upon our senior management team and key technical personnel; our energy market revenues’ dependence on conditions in the historically volatile oil and natural gas industries; and consolidation in the healthcare industry resulting in greater competition;\nstrategic risks, such as the intense competition we face and our ability to successfully market our products; our ability to respond to changes in technology; our ability to develop new products and expand into new geographic and product markets; and our ability to successfully identify, make and integrate acquisitions to expand and develop our business in accordance with expectations;\nfinancial and indebtedness risks, such as our ability to accurately forecast future performance based on operating results that often fluctuate; our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under the credit agreement governing our Senior Secured Credit Facilities; economic and credit market uncertainties that could interrupt our access to capital markets, borrowings or financial transactions; the conditional conversion feature of the 2028 Convertible Notes adversely impacting our liquidity, the conversion of our 2028 Convertible Notes, if it were to occur, diluting ownership interests of existing holders of our common stock; the counterparty risk associated with our capped call transaction; the counter financial and market risks related to our international operations and sales; our complex international tax profile; and our ability to realize the full value of our intangible assets;\nlegal and compliance risks, such as regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability or intellectual property claims; our ability to protect our intellectual property and proprietary rights; our ability to comply with customer-driven policies and third-party standards or certification requirements; our ability to obtain and/or retain necessary licenses from third parties for new technologies; our ability and the cost to comply with environmental regulations; legal and regulatory risks from our international operations; the fact that the healthcare industry is highly regulated and subject to various regulatory changes; and our business being indirectly subject to healthcare industry cost containment measures that could result in reduced sales of our products; and\nother risks and uncertainties that arise from time to time.\n\nExcept as may be required by law, we assume no obligation to update forward-looking statements in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.\n\n\n\nCondensed Consolidated Balance Sheets - Unaudited\n\n\n(in thousands)\n\n\n \n \n\n\n \nSeptember 27,2024\n \nDecember 31, 2023\n\n\nASSETS\n \n \n \n\n\nCurrent assets:\n \n \n \n\n\nCash and cash equivalents\n$\n35,574\n \n$\n23,674\n\n\nAccounts receivable, net\n \n241,708\n \n \n231,283\n\n\nInventories\n \n265,415\n \n \n229,102\n\n\nRefundable income taxes\n \n8,216\n \n \n1,998\n\n\nContract assets\n \n99,287\n \n \n85,871\n\n\nPrepaid expenses and other current assets\n \n24,956\n \n \n28,035\n\n\nCurrent assets of discontinued operations held for sale\n \n54,876\n \n \n17,705\n\n\nTotal current assets\n \n730,032\n \n \n617,668\n\n\nProperty, plant and equipment, net\n \n472,315\n \n \n392,569\n\n\nGoodwill\n \n   1,033,078\n \n \n994,007\n\n\nOther intangible assets, net\n \n805,174\n \n \n779,598\n\n\nDeferred income taxes\n \n6,782\n \n \n7,001\n\n\nOperating lease assets\n \n78,624\n \n \n81,319\n\n\nFinancing lease assets\n \n17,205\n \n \n11,675\n\n\nOther long-term assets\n \n24,439\n \n \n22,407\n\n\nNoncurrent assets of discontinued operations held for sale\n \n—\n \n \n36,409\n\n\nTotal assets\n$\n3,167,649\n \n$\n2,942,653\n\n\nLIABILITIES AND STOCKHOLDERS’ EQUITY\n \n \n \n\n\nCurrent liabilities:\n \n \n \n\n\nCurrent portion of long-term debt\n$\n5,000\n \n$\n—\n\n\nAccounts payable\n \n116,837\n \n \n118,258\n\n\nIncome taxes payable\n \n571\n \n \n3,896\n\n\nOperating lease liabilities\n \n8,883\n \n \n8,564\n\n\nAccrued expenses and other current liabilities\n \n86,138\n \n \n86,748\n\n\nCurrent liabilities of discontinued operations held for sale\n \n4,969\n \n \n3,503\n\n\nTotal current liabilities\n \n222,398\n \n \n220,969\n\n\nLong-term debt\n \n1,074,339\n \n \n959,925\n\n\nDeferred income taxes\n \n143,236\n \n \n143,552\n\n\nOperating lease liabilities\n \n69,115\n \n \n72,126\n\n\nFinancing lease liabilities\n \n13,996\n \n \n10,272\n\n\nOther long-term liabilities\n \n23,379\n \n \n14,303\n\n\nNoncurrent liabilities of discontinued operations held for sale\n \n—\n \n \n2,464\n\n\nTotal liabilities\n \n1,546,463\n \n \n1,423,611\n\n\nStockholders’ equity:\n \n \n \n\n\nCommon stock\n \n34\n \n \n33\n\n\nAdditional paid-in capital\n \n736,125\n \n \n727,435\n\n\nRetained earnings\n \n858,544\n \n \n771,351\n\n\nAccumulated other comprehensive income\n \n26,483\n \n \n20,223\n\n\nTotal stockholders’ equity\n \n1,621,186\n \n \n1,519,042\n\n\nTotal liabilities and stockholders’ equity\n$\n3,167,649\n \n$\n2,942,653\n\n\n\n\n\n\nCondensed Consolidated Statements of Operations - Unaudited\n \n \n \n \n\n\n(in thousands, except per share data)\n \n \n \n \n \n \n \n\n\n \n \n \n \n \n \n \n \n\n\n \nThree Months Ended\n \nNine Months Ended\n\n\n \nSeptember 27,2024\n \nSeptember 29,2023\n \nSeptember 27,2024\n \nSeptember 29,2023\n\n\nSales\n$\n431,417\n \n \n$\n396,803\n \n \n$\n1,267,099\n \n \n$\n1,151,152\n\n\nCost of sales\n \n314,849\n \n \n \n291,813\n \n \n \n924,881\n \n \n \n850,827\n\n\nGross profit\n \n116,568\n \n \n \n104,990\n \n \n \n342,218\n \n \n \n300,325\n\n\nOperating expenses:\n \n \n \n \n \n \n \n\n\nSelling, general and administrative\n \n44,820\n \n \n \n41,444\n \n \n \n137,734\n \n \n \n127,875\n\n\nResearch, development and engineering\n \n11,923\n \n \n \n14,068\n \n \n \n42,811\n \n \n \n48,917\n\n\nRestructuring and other charges\n \n1,814\n \n \n \n702\n \n \n \n10,467\n \n \n \n3,742\n\n\nTotal operating expenses\n \n58,557\n \n \n \n56,214\n \n \n \n191,012\n \n \n \n180,534\n\n\nOperating income\n \n58,011\n \n \n \n48,776\n \n \n \n151,206\n \n \n \n119,791\n\n\nInterest expense\n \n14,577\n \n \n \n11,493\n \n \n \n43,140\n \n \n \n39,221\n\n\n(Gain) loss on equity investments\n \n(906\n)\n \n \n3,451\n \n \n \n(2,035\n)\n \n \n3,472\n\n\nOther loss, net\n \n916\n \n \n \n580\n \n \n \n1,796\n \n \n \n1,699\n\n\nIncome from continuing operations before taxes\n \n43,424\n \n \n \n33,252\n \n \n \n108,305\n \n \n \n75,399\n\n\nProvision for income taxes\n \n7,142\n \n \n \n5,078\n \n \n \n20,225\n \n \n \n13,069\n\n\nIncome from continuing operations\n \n36,282\n \n \n \n28,174\n \n \n \n88,080\n \n \n \n62,330\n\n\nIncome (loss) from discontinued operations, net of tax\n \n(843\n)\n \n \n(917\n)\n \n \n(887\n)\n \n \n1,963\n\n\nNet income\n$\n35,439\n \n \n$\n27,257\n \n \n$\n87,193\n \n \n$\n64,293\n\n\n \n \n \n \n \n \n \n \n\n\nBasic earnings per share:\n \n \n \n \n \n \n \n\n\nIncome from continuing operations\n$\n1.08\n \n \n$\n0.84\n \n \n$\n2.62\n \n \n$\n1.87\n\n\nIncome (loss) from discontinued operations\n$\n(0.03\n)\n \n$\n(0.03\n)\n \n$\n(0.03\n)\n \n$\n0.06\n\n\nBasic earnings per share\n$\n1.05\n \n \n$\n0.82\n \n \n$\n2.60\n \n \n$\n1.93\n\n\n \n \n \n \n \n \n \n \n\n\nDiluted earnings per share:\n \n \n \n \n \n \n \n\n\nIncome from continuing operations\n$\n1.01\n \n \n$\n0.83\n \n \n$\n2.49\n \n \n$\n1.85\n\n\nIncome (loss) from discontinued operations\n$\n(0.02\n)\n \n$\n(0.03\n)\n \n$\n(0.03\n)\n \n$\n0.06\n\n\nDiluted earnings per share\n$\n0.99\n \n \n$\n0.81\n \n \n$\n2.46\n \n \n$\n1.91\n\n\n \n \n \n \n \n \n \n \n\n\nWeighted average shares outstanding:\n \n \n \n \n \n \n \n\n\nBasic\n \n33,656\n \n \n \n33,346\n \n \n \n33,579\n \n \n \n33,305\n\n\nDiluted\n \n35,791\n \n \n \n33,774\n \n \n \n35,441\n \n \n \n33,679\n\n\n\n\n\n\nCondensed Consolidated Statements of Cash Flows - Unaudited (a)\n\n\n(in thousands)\n\n\n \n \n\n\n \nNine Months Ended\n\n\n \nSeptember 27,2024\n \nSeptember 29,2023\n\n\nCash flows from operating activities:\n \n \n \n\n\nNet income\n$\n87,193\n \n \n$\n 64,293\n \n\n\nAdjustments to reconcile net income to net cash provided by operating activities:\n \n \n \n\n\nDepreciation and amortization\n \n82,104\n \n \n \n73,116\n \n\n\nDebt related charges included in interest expense\n \n2,962\n \n \n \n7,126\n \n\n\nInventory step-up amortization\n \n1,056\n \n \n \n—\n \n\n\nStock-based compensation\n \n18,729\n \n \n \n17,099\n \n\n\nNon-cash lease expense\n \n6,928\n \n \n \n8,124\n \n\n\nNon-cash (gain) loss on equity investments\n \n(2,035\n)\n \n \n3,472\n \n\n\nContingent consideration fair value adjustment\n \n—\n \n \n \n(526\n)\n\n\nOther non-cash (gains) losses\n \n4,433\n \n \n \n(734\n)\n\n\nDeferred income taxes\n \n—\n \n \n \n(5\n)\n\n\nChanges in operating assets and liabilities, net of acquisition:\n \n \n \n\n\nAccounts receivable\n \n(4,888\n)\n \n \n(58\n)\n\n\nInventories\n \n(31,515\n)\n \n \n(25,785\n)\n\n\nPrepaid expenses and other assets\n \n(495\n)\n \n \n(1,473\n)\n\n\nContract assets\n \n(13,159\n)\n \n \n(14,863\n)\n\n\nAccounts payable\n \n4,295\n \n \n \n(869\n)\n\n\nAccrued expenses and other liabilities\n \n(5,355\n)\n \n \n7,401\n \n\n\nIncome taxes payable\n \n(8,279\n)\n \n \n(11,692\n)\n\n\nNet cash provided by operating activities\n \n141,974\n \n \n \n124,626\n \n\n\nCash flows from investing activities:\n \n \n \n\n\nAcquisition of property, plant and equipment\n \n(86,267\n)\n \n \n(82,885\n)\n\n\nPurchase of intangible asset\n \n(250\n)\n \n \n—\n \n\n\nProceeds from sale of property, plant and equipment\n \n30\n \n \n \n100\n \n\n\nAcquisitions, net\n \n(138,544\n)\n \n \n—\n \n\n\nNet cash used in investing activities\n \n(225,031\n)\n \n \n(82,785\n)\n\n\nCash flows from financing activities:\n \n \n \n\n\nPrincipal payments of long-term debt\n \n(2\n)\n \n \n(415,938\n)\n\n\nProceeds from issuance of convertible notes, net of discount\n \n—\n \n \n \n486,250\n \n\n\nProceeds from revolving credit facility\n \n234,500\n \n \n \n294,603\n \n\n\nPayments of revolving credit facility\n \n(117,500\n)\n \n \n(353,993\n)\n\n\nPurchase of capped calls\n \n—\n \n \n \n(35,000\n)\n\n\nPayment of debt issuance costs\n \n(2,071\n)\n \n \n(2,181\n)\n\n\nProceeds from the exercise of stock options\n \n742\n \n \n \n2,303\n \n\n\nTax withholdings related to net share settlements of restricted stock unit awards\n \n(10,773\n)\n \n \n(3,067\n)\n\n\nContingent consideration payments\n \n—\n \n \n \n(7,660\n)\n\n\nPrincipal payments on finance leases\n \n(9,772\n)\n \n \n(854\n)\n\n\nOther financing activities\n \n501\n \n \n \n—\n \n\n\nNet cash provided by (used in) financing activities\n \n95,625\n \n \n \n(35,537\n)\n\n\nEffect of foreign currency exchange rates on cash and cash equivalents\n \n(668\n)\n \n \n1,566\n \n\n\nNet increase in cash and cash equivalents\n \n11,900\n \n \n \n7,870\n \n\n\nCash and cash equivalents, beginning of period\n \n23,674\n \n \n \n24,272\n \n\n\nCash and cash equivalents, end of period\n$\n35,574\n \n \n$\n32,142\n \n\n\n\n\n\n\n(a)\nThe Condensed Consolidated Statements of Cash Flows - Unaudited includes cash flows related to discontinued operations.\n\n\n\nTable A: Adjusted Net Income and Diluted EPS from Continuing Operations Reconciliations(in thousands, except per share amounts)\n\n\n\n \nThree Months Ended\n\n\n \nSeptember 27, 2024\n \nSeptember 29, 2023\n\n\n \nPre-Tax\n \nNet of Tax\n \nPerDilutedShare(a)\n \nPre-Tax\n \nNet of Tax\n \nPerDilutedShare(a)\n\n\nIncome from continuing operations (GAAP)\n$\n43,424\n \n \n$\n36,282\n \n \n$\n1.01\n \n \n$\n33,252\n \n$\n28,174\n \n$\n0.83\n\n\nAdjustments(b):\n \n \n \n \n \n \n \n \n \n \n \n\n\nAmortization of intangible assets\n \n13,626\n \n \n \n10,972\n \n \n \n0.32\n \n \n \n13,021\n \n \n10,292\n \n \n0.30\n\n\nCertain legal expenses (SG&A)(c)\n \n481\n \n \n \n381\n \n \n \n0.01\n \n \n \n—\n \n \n—\n \n \n—\n\n\nRestructuring and restructuring-related charges(d)\n \n1,916\n \n \n \n1,467\n \n \n \n0.04\n \n \n \n470\n \n \n444\n \n \n0.01\n\n\nAcquisition and integration costs(e)\n \n1,017\n \n \n \n800\n \n \n \n0.02\n \n \n \n777\n \n \n580\n \n \n0.02\n\n\nOther general expenses(f)\n \n83\n \n \n \n76\n \n \n \n—\n \n \n \n28\n \n \n28\n \n \n—\n\n\n(Gain) loss on equity investments(g)\n \n(906\n)\n \n \n(716\n)\n \n \n(0.02\n)\n \n \n3,451\n \n \n2,726\n \n \n0.08\n\n\nLoss on extinguishment of debt(h)\n \n—\n \n \n \n—\n \n \n \n—\n \n \n \n87\n \n \n68\n \n \n—\n\n\nMedical device regulations(i)\n \n209\n \n \n \n165\n \n \n \n—\n \n \n \n205\n \n \n164\n \n \n—\n\n\nOther adjustments(j)\n \n304\n \n \n \n240\n \n \n \n0.01\n \n \n \n1,319\n \n \n1,042\n \n \n0.03\n\n\nTax adjustments(k)\n \n—\n \n \n \n165\n \n \n \n—\n \n \n \n—\n \n \n120\n \n \n—\n\n\nImpact of capped call option contracts\n \n—\n \n \n \n—\n \n \n \n0.03\n \n \n \n—\n \n \n—\n \n \n—\n\n\nAdjusted net income (non-GAAP)\n$\n60,154\n \n \n$\n49,832\n \n \n$\n1.43\n \n \n$\n52,610\n \n$\n43,638\n \n$\n1.29\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n\n\nWeighted average shares for diluted EPS (GAAP)\n \n \n \n35,791\n \n \n \n \n \n \n \n33,774\n \n \n\n\nLess: 2028 Convertible Notes capped call options impact\n \n \n \n(1,003\n)\n \n \n \n \n \n \n—\n \n \n\n\nAdjusted weighted average shares (non-GAAP)\n \n \n \n34,788\n \n \n \n \n \n \n \n33,774\n \n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \nNine Months Ended\n\n\n \nSeptember 27, 2024\n \nSeptember 29, 2023\n\n\n \nPre-Tax\n \nNet of Tax\n \nPerDilutedShare(a)\n \nPre-Tax\n \nNet of Tax\n \nPerDilutedShare(a)\n\n\nIncome from continuing operations (GAAP)\n$\n108,305\n \n \n$\n88,080\n \n \n$\n2.49\n \n \n$\n75,399\n \n$\n62,330\n \n$\n1.85\n\n\nAdjustments(b):\n \n \n \n \n \n \n \n \n \n \n \n\n\nAmortization of intangible assets\n \n40,586\n \n \n \n32,668\n \n \n \n0.95\n \n \n \n38,884\n \n \n30,735\n \n \n0.91\n\n\nCertain legal expenses (SG&A)(c)\n \n835\n \n \n \n660\n \n \n \n0.02\n \n \n \n—\n \n \n—\n \n \n—\n\n\nRestructuring and restructuring-related charges(d)\n \n5,738\n \n \n \n4,569\n \n \n \n0.13\n \n \n \n5,162\n \n \n4,120\n \n \n0.12\n\n\nAcquisition and integration costs(e)\n \n8,408\n \n \n \n6,658\n \n \n \n0.19\n \n \n \n1,715\n \n \n1,282\n \n \n0.04\n\n\nOther general expenses(f)\n \n(972\n)\n \n \n(653\n)\n \n \n(0.02\n)\n \n \n137\n \n \n107\n \n \n—\n\n\n(Gain) loss on equity investments(g)\n \n(2,035\n)\n \n \n(1,608\n)\n \n \n(0.05\n)\n \n \n3,472\n \n \n2,743\n \n \n0.08\n\n\nLoss on extinguishment of debt(h)\n \n—\n \n \n \n—\n \n \n \n—\n \n \n \n4,518\n \n \n3,569\n \n \n0.11\n\n\nMedical device regulations(i)\n \n762\n \n \n \n602\n \n \n \n0.02\n \n \n \n1,241\n \n \n981\n \n \n0.03\n\n\nOther adjustments(j)\n \n1,048\n \n \n \n828\n \n \n \n0.02\n \n \n \n2,228\n \n \n1,760\n \n \n0.05\n\n\nInventory step-up amortization (COS)(l)\n \n1,056\n \n \n \n834\n \n \n \n0.02\n \n \n \n—\n \n \n—\n \n \n—\n\n\nTax adjustments(k)\n \n—\n \n \n \n545\n \n \n \n0.02\n \n \n \n—\n \n \n249\n \n \n0.01\n\n\nImpact of capped call option contracts\n \n—\n \n \n \n—\n \n \n \n0.07\n \n \n \n—\n \n \n—\n \n \n—\n\n\nAdjusted net income (Non-GAAP)\n$\n163,731\n \n \n$\n133,183\n \n \n$\n3.87\n \n \n$\n132,756\n \n$\n107,876\n \n$\n3.20\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n\n\nWeighted average shares for diluted EPS (GAAP)\n \n \n \n 35,441\n \n \n \n \n \n \n \n   33,679\n \n \n\n\nLess: 2028 Convertible Notes capped call options impact\n \n \n \n(1,027\n)\n \n \n \n \n \n \n—\n \n \n\n\nAdjusted weighted average shares (non-GAAP)\n \n \n \n34,414\n \n \n \n \n \n \n \n33,679\n \n \n\n\n\n\n\n\n(a)\nIncome from continuing operations (GAAP) per diluted share amounts are calculated in accordance with GAAP using weighted average shares for diluted EPS. The per share amounts for the adjustments in the table above and adjusted net income are calculated using adjusted weighted average shares. \n\n\n(b)\nThe difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are computed using a 21% U.S. tax rate, and the statutory tax rates applicable in foreign tax jurisdictions, as adjusted for the existence of net operating losses (“NOLs”). Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%. \n\n\n(c)\nCertain legal expenses associated with non-ordinary course legal matters. \n\n\n(d)\nWe initiate discrete restructuring programs primarily to realign resources to better serve our customers and markets, improve operational efficiency and capabilities, and lower operating costs or improve profitability. Depending on the program, restructuring charges may include termination benefits, contract termination, facility closure and other exit and disposal costs. Restructuring-related expenses are directly related to the program and may include retention bonuses, accelerated depreciation, consulting expense and costs to transfer manufacturing operations among our facilities.\n\n\n(e)\nAcquisition and integration costs are incremental costs that are directly related to a business or asset acquisition. These costs may include, among other things, professional, consulting and other fees, system integration costs, and fair value adjustments relating to contingent consideration.\n\n\n(f)\nOther general expenses are discrete transactions occurring sporadically and affect period-over-period comparisons. The expenses for the 2024 and 2023 periods include gains and losses in connection with the disposal of property, plant and equipment. In addition, during the second quarter of 2024, we recorded $1.2 million of loss recoveries relating to property damage which occurred in the fourth quarter of 2023 at one of our manufacturing facilities.\n\n\n(g)\nAmounts reflect our share of equity method investee (gains) losses including unrealized appreciation/depreciation of the underlying interests of the investee.\n\n\n(h)\nLoss on extinguishment of debt consists of accelerated write-offs of unamortized deferred debt issuance costs and discounts, which are included in interest expense. The 2023 amount represents a write-off of unamortized deferred debt issuance costs and discounts in connection with the amendments to the credit agreement governing our credit facilities, prepayments of portions of the Term Loan A Facility, and repayment in full of the Term Loan B Facility.\n\n\n(i)\nThe charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.\n\n\n(j)\nAmount primarily relates to costs associated with certain formal strategic projects. Strategic projects primarily involve system reconfiguration to support our manufacturing excellence operational strategic imperative and investments in certain technology and platform development to align our capabilities to meet customer needs.\n\n\n(k)\nTax adjustments predominately relate to acquired foreign tax credits, including utilization, changes to uncertain tax benefits and associated interest.\n\n\n(l)\nThe accounting associated with our acquisitions require us to record inventory at its fair value, which is sometimes greater than the previous book value of inventory. The increase in inventory value is amortized to cost of sales over the period that the related inventory is sold. We exclude inventory step-up amortization from our non-GAAP financial measures because it is a non-cash expense that we do not believe is indicative of our ongoing operating results.\n\n\n\nPlease see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures.\nTable B: Adjusted Operating Income Reconciliations(in thousands)\n\n\n\n \nThree Months Ended\n \nNine Months Ended\n\n\n \nSeptember 27,2024\n \nSeptember 29,2023\n \nSeptember 27,2024\n \nSeptember 29,2023\n\n\nOperating income (GAAP)\n$\n58,011\n \n$\n48,776\n \n$\n151,206\n \n \n$\n119,791\n\n\nAdjustments:\n \n \n \n \n \n \n \n\n\nAmortization of intangible assets\n \n13,626\n \n \n13,021\n \n \n40,586\n \n \n \n38,884\n\n\nCertain legal expenses\n \n481\n \n \n—\n \n \n835\n \n \n \n—\n\n\nRestructuring and restructuring-related charges\n \n1,916\n \n \n470\n \n \n5,738\n \n \n \n5,162\n\n\nAcquisition and integration costs\n \n1,017\n \n \n777\n \n \n8,408\n \n \n \n1,715\n\n\nOther general expenses\n \n83\n \n \n28\n \n \n(972\n)\n \n \n137\n\n\nMedical device regulations\n \n209\n \n \n205\n \n \n762\n \n \n \n1,241\n\n\nOther adjustments\n \n304\n \n \n1,319\n \n \n1,048\n \n \n \n2,228\n\n\nInventory step-up amortization\n \n—\n \n \n—\n \n \n1,056\n \n \n \n—\n\n\nAdjusted operating income (non-GAAP)\n$\n75,647\n \n$\n64,596\n \n$\n208,667\n \n \n$\n169,158\n\n\n\nTable C: EBITDA Reconciliations(in thousands)\n\n\n\n \nThree Months Ended\n \nNine Months Ended\n\n\n \nSeptember 27,2024\n \nSeptember 29,2023\n \nSeptember 27,2024\n \nSeptember 29,2023\n\n\nIncome from continuing operations (GAAP)\n$\n36,282\n \n \n$\n28,174\n \n$\n88,080\n \n \n$\n62,330\n\n\n \n \n \n \n \n \n \n \n\n\nInterest expense\n \n14,577\n \n \n \n  11,493\n \n \n43,140\n \n \n \n39,221\n\n\nProvision for income taxes\n \n7,142\n \n \n \n5,078\n \n \n20,225\n \n \n \n13,069\n\n\nDepreciation(a)\n \n14,025\n \n \n \n10,836\n \n \n38,424\n \n \n \n32,337\n\n\nAmortization of intangible assets and financing leases\n \n14,320\n \n \n \n13,363\n \n \n42,356\n \n \n \n39,882\n\n\nEBITDA (non-GAAP)\n \n86,346\n \n \n \n68,944\n \n \n232,225\n \n \n \n186,839\n\n\nStock-based compensation(a)\n \n6,076\n \n \n \n5,487\n \n \n18,532\n \n \n \n16,875\n\n\nCertain legal expenses\n \n481\n \n \n \n—\n \n \n835\n \n \n \n—\n\n\nRestructuring and restructuring-related charges\n \n1,916\n \n \n \n470\n \n \n5,738\n \n \n \n5,162\n\n\nAcquisition and integration costs\n \n1,017\n \n \n \n777\n \n \n8,408\n \n \n \n1,715\n\n\nOther general expenses\n \n83\n \n \n \n28\n \n \n(972\n)\n \n \n137\n\n\n(Gain) loss on equity investments\n \n(906\n)\n \n \n3,451\n \n \n(2,035\n)\n \n \n3,472\n\n\nMedical device regulations\n \n209\n \n \n \n205\n \n \n762\n \n \n \n1,241\n\n\nOther adjustments\n \n304\n \n \n \n1,319\n \n \n1,048\n \n \n \n2,228\n\n\nInventory step-up amortization\n \n—\n \n \n \n—\n \n \n1,056\n \n \n \n—\n\n\nAdjusted EBITDA (non-GAAP)\n$\n95,526\n \n \n$\n80,681\n \n$\n265,597\n \n \n$\n217,669\n\n\n\n\n\n\n(a)\nExcludes amounts included in Restructuring and restructuring-related charges.\n\n\n\nTable D: Organic Sales Change Reconciliation (% Change)\n\n\n\n \nGAAP Reported Growth\n \nImpact of Foreign Currency(a)\n \nImpact of Strategic Exits and Acquisitions(a)\n \nNon-GAAP Organic Change\n\n\nQTD Change (3Q 2024 vs. 3Q 2023)\n \n \n \n \n \n \n \n\n\nProduct Line\n \n \n \n \n \n \n \n\n\nCardio & Vascular\n12.6%\n \n0.1%\n \n6.3%\n \n6.2%\n\n\nCardiac Rhythm Management & Neuromodulation\n3.1%\n \n—%\n \n0.9%\n \n2.2%\n\n\nAdvanced Surgical, Orthopedics & Portable Medical\n11.6%\n \n—%\n \n12.6%\n \n(1.0)%\n\n\nTotal Sales\n8.7%\n \n0.1%\n \n4.3%\n \n4.3%\n\n\n \n \n \n \n \n \n \n \n\n\nYTD Change (9M 2024 vs. 9M 2023)\n \n \n \n \n \n \n \n\n\nProduct Line\n \n \n \n \n \n \n \n\n\nCardio & Vascular\n13.1%\n \n0.1%\n \n6.6%\n \n6.5%\n\n\nCardiac Rhythm Management & Neuromodulation\n6.6%\n \n—%\n \n0.9%\n \n5.7%\n\n\nAdvanced Surgical, Orthopedics & Portable Medical\n6.3%\n \n—%\n \n(0.2)%\n \n6.5%\n\n\nTotal Sales\n10.1%\n \n—%\n \n3.9%\n \n6.2%\n\n\n\n\n\n\n(a) \nSales growth has been adjusted to exclude the impact of foreign currency exchange rate fluctuations and acquisitions and strategic exits.\n\n\n\nTable E: Net Total Debt Reconciliation(in thousands)\n\n\n\n \nSeptember 27,2024\n \nDecember 31,2023\n\n\nTotal debt\n$\n1,079,339\n \n$\n959,925\n\n\nAdd: Debt discounts and deferred issuance costs included in Total debt\n \n11,659\n \n \n14,075\n\n\nTotal principal amount of debt outstanding\n \n1,090,998\n \n \n974,000\n\n\nLESS: Cash and cash equivalents\n \n35,574\n \n \n23,674\n\n\nNet Total Debt (Non-GAAP)\n$\n1,055,424\n \n$\n950,326","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477682169"}